BioAtla Raises $100 Million from Sinobioway in Drug Development Deal

BioAtla, a San Diego-Beijing biotech, reported that it has now received over $100 million from Sinobioway of Beijing in a deal that grants Sinobioway greater China rights to four BioAtla drug candidates. The two companies have selected four molecules (which were not disclosed) to include in the collaboration, triggering a $35 million payment that put the deal value over $100 million. BioAtla is developing a portfolio of Conditionally Active Biologic antibody therapeutics, which remain encapsulated until they are released in specific microenvironments. One year ago, BioAtla signed a deal with Pfizer that could be worth $1 billion. More details.... Stock Symbol: (NYSE: PFE) Share this with colleagues: // //